LES 2006 Annual Meeting - Licensing and Business Issues
6-E Pharmaceutical Company Spin-Offs: Licensing and Business Issues
As Big Pharma continues to consolidate and refocus its R&D programs, spin offs of R&D or other business units are increasingly common. This Workshop will discuss some of many issues arising from these spinoffs, including structuring the intellectual property, dealing with options and other rights to products developed by the spinoffs, and handling future business and scientific relationships. Case studies will be discussed from transactions in which the speakers were involved, including Pharmacia's spinoff of Biovitrum AB and Novo Nordisk's spinoff of Zymogenetics, Inc.
- James Farrington, Partner, Wiggin and Dana
- Fredrik Henell, Zymogenetics, Inc.
- Usha Pillai, Pfzer Global Research & Development